CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $54.25B, higher than 95% of all stocks globally
- FinancialsAltman Z-Score 5.43: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
47.00BEUR54.25B · vs all stocks (USD)
Trailing P/E
138.62xvs Biotechnology peers
Revenue (TTM)
5.11BEUR5.90B · vs all stocks (USD)
Profit Margin
6.46%vs Biotechnology peers
Beta
0.3365xvs all stocks
52-Week Change
35.52%vs all stocks
Market Capitalization
47.00BEUR54.25B · vs all stocks (USD)
Enterprise Value
16.12BEUR18.61B · vs all stocks (USD)
Trailing P/E
138.62xvs Biotechnology peers
Price to Sales (TTM)
9.38xvs Biotechnology peers
Price to Book (MRQ)
4.94xvs Biotechnology peers
Enterprise to Revenue
3.15xvs Biotechnology peers
Enterprise to EBITDA
14.20xvs Biotechnology peers
Profit Margin
6.46%vs Biotechnology peers
Operating Margin
10.64%vs Biotechnology peers
Return on Assets (TTM)
2.15%vs Biotechnology peers
Return on Equity (TTM)
3.70%vs Biotechnology peers
Revenue (TTM)
5.11BEUR5.90B · vs all stocks (USD)
Revenue per Share (TTM)
26.99EURUpdated Jul 14, 2026Quarterly Revenue Growth
-11.80%vs Biotechnology peers
Gross Profit (TTM)
3.48BEUR4.02B · vs all stocks (USD)
EBITDA (TTM)
2.57BEUR2.97B · vs all stocks (USD)
Net Income (TTM)
332.00MEUR383.22M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-22.10%vs Biotechnology peers
Operating Cash Flow (TTM)
975.00MEUR1.13B · vs all stocks (USD)
Levered Free Cash Flow (TTM)
479.75MEUR553.77M · vs all stocks (USD)
5-Year Average Dividend Yield
1.53%vs all stocks
Payout Ratio
78.24%vs Biotechnology peers
Minority Interest (Equity)
0.00EURFY2025 · Dec 31, 2025Revenue
7.74BEURFY2025 · Dec 31, 2025Cost of Goods Sold
1.99BEURFY2025 · Dec 31, 2025Gross Profit
5.75BEURFY2025 · Dec 31, 2025Operating Income
2.00BEUR2.31B · vs all stocks (USD)
Pre-tax Income
1.82BEURFY2025 · Dec 31, 2025Income Tax Expense
264.00MEURFY2025 · Dec 31, 2025Net Income
1.56BEURFY2025 · Dec 31, 2025EBIT
1.95BEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.57BEURFY2025 · Dec 31, 2025Research & Development
1.82BEURFY2025 · Dec 31, 2025Selling, General & Administrative
2.75BEURFY2025 · Dec 31, 2025Other Operating Expenses
20.00MEURFY2025 · Dec 31, 2025Non-operating Interest Income
46.00MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
128.00MEURFY2025 · Dec 31, 2025EPS (Basic)
8.20EURFY2025 · Dec 31, 2025EPS (Diluted)
8.03EURFY2025 · Dec 31, 2025Basic Shares Outstanding
190.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
190.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.56BEURFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00EURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
1.02BEURFY2025 · Dec 31, 2025Free Cash Flow
745.00MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.25BEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.56BEURFY2025 · Dec 31, 2025Stock-based Compensation
-10.00MEURFY2025 · Dec 31, 2025Other Non-cash Items
48.00MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-368.00MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-203.00MEURFY2025 · Dec 31, 2025Capital Expenditures
-280.00MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-168.00MEURFY2025 · Dec 31, 2025Net Acquisitions
-11.00MEURFY2025 · Dec 31, 2025Purchase of Investments
-18.00MEURFY2025 · Dec 31, 2025Sale of Investments
88.00MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-221.00MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00EURFY2025 · Dec 31, 2025Long-term Debt Payments
-641.00MEURFY2025 · Dec 31, 2025Common Stock Repurchase
-121.00MEURFY2025 · Dec 31, 2025Common Dividends Paid
-264.00MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.03BEURFY2025 · Dec 31, 2025Shares Outstanding
190.36MSharesUpdated Jul 14, 2026Float Shares
120.28MSharesUpdated Jul 14, 2026% Held by Insiders
38.04%vs all stocks
% Held by Institutions
40.79%vs all stocks
Total Cash (MRQ)
457.00MEUR527.51M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.41EURUpdated Jul 14, 2026Total Debt (MRQ)
2.90BEUR3.34B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3203xvs Biotechnology peers
Current Ratio (MRQ)
1.13xvs Biotechnology peers
Book Value per Share (MRQ)
47.66EURUpdated Jul 14, 2026Total Assets
18.16BEUR20.96B · vs all stocks (USD)
Total Current Assets
6.05BEURFY2025 · Dec 31, 2025Total Liabilities
7.29BEURFY2025 · Dec 31, 2025Total Non-current Assets
12.10BEURFY2025 · Dec 31, 2025Total Non-current Liabilities
2.89BEURFY2025 · Dec 31, 2025Total Current Liabilities
4.40BEURFY2025 · Dec 31, 2025Cash
223.00MEURFY2025 · Dec 31, 2025Cash Equivalents
2.03BEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.25BEURFY2025 · Dec 31, 2025Other Short-term Investments
196.00MEURFY2025 · Dec 31, 2025Accounts Receivable
1.33BEURFY2025 · Dec 31, 2025Inventory
1.50BEURFY2025 · Dec 31, 2025Accounts Payable
817.00MEURFY2025 · Dec 31, 2025Short-term Debt
62.00MEURFY2025 · Dec 31, 2025Long-term Debt
2.18BEURFY2025 · Dec 31, 2025Common Stock (Book)
584.00MEURFY2025 · Dec 31, 2025Retained Earnings
8.68BEURFY2025 · Dec 31, 2025Total Shareholders' Equity
10.87BEUR12.54B · vs all stocks (USD)
Treasury Stock
389.00MEURFY2025 · Dec 31, 202552-Week Low
168.55EURUpdated Jul 14, 202652-Week High
289.50EURUpdated Jul 14, 202652-Week Change
35.52%vs all stocks
Beta
0.3365xvs all stocks
50-Day MA
249.37EURUpdated Jul 14, 2026200-Day MA
249.44EURUpdated Jul 14, 2026Avg 10-Day Volume
31.43KSharesUpdated Jul 14, 2026Avg 30-Day Volume
47.29KSharesUpdated Jul 14, 2026Diluted EPS (TTM)
1.70EURUpdated Jul 14, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.43: safe zoneNotable
Altman Z-Score: 5.43
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $54.25B, higher than 95% of all stocks globallySignificant
Market cap (USD): 54,253,711,009.418Global P95: 25,614,208,870.135
Revenue is $5.9B, above the global median of $520.53MNotable
Revenue (USD): 5,899,576,263.875Global Median: 520,528,949.311
Levered free cash flow is $553.77M, above the global median of $16.24MNotable
Levered free cash flow (USD): 553,770,645.969Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Bayer AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Siemens Healthineers AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Samsung Biologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Edwards Lifesciences Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sun Pharmaceutical Industries Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beigene Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
argenx SE
Tier 1ProductionApproval-Gated PipelineRule
Boston Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Haleon plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Franklin Electric Co., Inc.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Fiem Industries Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
GEA Group AG
1 interpretationIndustry-Benchmarked Return on Capital Elevated